268 results about "Resistant organism" patented technology

The invention discloses a spatio-temporal trajectory fusion-based closed-loop monitoring method and system for drug-resistant bacteria in a hospital. The method comprises the following steps: collecting and processing strain drug sensitive test results and patient clinical index data in a hospital information system, and screening out key features through an improved genetic algorithm; wherein the clinical index data of the patient comprises original spatio-temporal trajectory data and nursing operation records; analyzing spatio-temporal trajectory data of the patient according to the key features, combining with drug sensitivity spectrum consistency, and constructing a propagation network model by using a graph convolutional network to identify infection source nodes and corresponding topological influence; and generating an early warning signal based on the topological influence of the infection source node, and continuously optimizing prevention and control measures by dynamically adjusting model parameters and a real-time feedback mechanism. By implementing the method provided by the invention, accurate analysis and real-time prevention and control of a drug-resistant bacterium transmission link can be realized.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mh-GC21 as well as a precursor and application thereof. The amino acid sequence of the antibacterial peptide Mh-GC21 provided by the invention is as shown in SEQ ID NO.1, and two cysteines are oxidized to form a pair of intermolecular disulfide bonds; the C tail end of the antibacterial peptide Mh-GC21 is subjected to amidation modification. The antibacterial peptide Mh-GC21 provided by the invention is from microhyla microcarpa, has broad-spectrum antibacterial activity, has relatively good antibacterial and bactericidal effects on standard strains of acinetobacter baumannii, escherichia coli and staphylococcus aureus and clinically sourced drug-resistant strains, and can be used for targeted destruction of cell membranes of bacteria, removal of biological membranes and inhibition of formation of the biological membranes. Moreover, the antibacterial peptide Mh-GC21 has the advantages of good stability, no hemolytic activity and cytotoxicity, and difficulty in inducing strains to generate drug resistance.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an LL-37 derived antibacterial peptide and application thereof. According to the invention, 17-29aa of the LL-37 antibacterial peptide is used as a core fragment and is connected with an amino acid sequence shown as SEQ ID NO: 1 or SEQ ID NO: 2 through an amido bond, the antibacterial activity of the obtained antibacterial peptide is obviously higher than that of the LL-37 antibacterial peptide, and the antibacterial peptide shows an obvious bactericidal effect on clinical drug-resistant bacteria such as acinetobacter baumannii, pseudomonas aeruginosa, escherichia coli, staphylococcus aureus, klebsiella pneumoniae and the like; meanwhile, the cytotoxicity and hemolytic activity are weak, drug resistance is not prone to being generated, bacteria can be rapidly killed in vivo through multiple mechanisms, no obvious cytotoxicity exists, the bacterium load in tissue is remarkably reduced, and the lifetime of a bacterium-infected mouse is prolonged.

The invention discloses bioactive gel for accelerating wound healing. The gel is prepared from the following raw materials in percentage by weight: 0.8%-1% of bomer 980, 5%-5.5% of glycerol, 15%-20% of white vaseline, 51.7%-55% of phosphate buffer, 1.8%-2% of nano royal jelly acid, 2%-3% of recombinant III type human collagen, 0.4%-0.5% of sodium hyaluronate, 1%-3% of sodium alginate, 20%-25% of polyethylene glycol-400, 1.5%-3% of dopamine-methacrylamide copolymer, 0.5%-0.8% of nano silver and 0.3%-0.5% of phenoxyethanol. The nano royal jelly acid and the nano silver have a synergistic antibacterial effect, so that the inhibition effect on drug-resistant bacteria such as MRSA and pseudomonas aeruginosa is remarkably improved, and meanwhile, the wound epithelization can be accelerated and scar formation can be reduced through the dual effects of the recombinant III type collagen and the acetylated sodium hyaluronate. The defects that a traditional dressing is narrow in antibacterial spectrum, single in repairing effect, poor in environmental adaptability and the like are overcome, and the dressing is particularly suitable for complicated wounds such as diabetic foot ulcer and second-degree burn.

The invention discloses a multi-drug-resistant bacterium infection risk assessment method, system and device and a storage medium, and belongs to the technical field of medical data analysis, and the method comprises the steps: collecting a clinical related data set of an ICU patient, and carrying out the preprocessing of the clinical related data set to obtain a to-be-assessed data set; performing feature extraction on the to-be-evaluated data set in combination with a long short-term memory network and a time sequence attention mechanism to obtain a high-risk feature set; inputting the high-risk feature set into a pre-constructed dynamic scoring model, and calculating a corresponding risk score through the dynamic scoring model; and grading the risk score based on a preset grading rule to obtain a current risk level, and outputting a corresponding intervention strategy through a preset intervention decision mechanism based on the current risk level. According to the scheme, the high-risk feature set is extracted by combining the long-short-term memory network with the time sequence attention mechanism, then the risk score is calculated through the dynamic scoring model, the risk level is determined according to the preset grading rule, the intervention strategy is output, and the accuracy of MDRO infection assessment is improved.

The invention relates to the field of drug-resistant bacterium infection, and discloses a g-C3N4 / Bi2Se3 nano heterojunction and a preparation method thereof.The preparation method comprises the steps that firstly, melamine powder is heated and calcined at the constant temperature, after a tubular furnace is naturally cooled, spark plasma sintering is conducted, nitrogen vacancies are introduced at the same time, and a blocky high-defect g-C3N4 material is obtained; grinding into powder, adding deionized water for ultrasonic treatment to obtain a first suspension, performing centrifugal treatment, freeze-drying the supernatant, and adding into an ethylene glycol solvent to obtain a second suspension; eG, polyvinylpyrrolidone, Bi (NO3) 3.5 H2O and Na2SeO3 are mixed and stirred, and the second turbid liquid is added; the preparation method comprises the following steps: adding Bi2Se3 into a reaction kettle, heating while stirring, adding a hydroxylamine EG solution, cooling to room temperature after reaction, centrifuging, washing, and carrying out vacuum drying on a precipitate to obtain a g-C3N4 / Bi2Se3 nano heterojunction; the problems that in the prior art, the catalytic efficiency is low, a collaborative mechanism does not achieve structure-function integrated design, the performance of a key functional material is limited, and the structural stability and biological suitability of the material are insufficient are solved.

The invention discloses an early warning method and system for outbreak of drug-resistant bacteria in a hospital based on dynamic aggregation degree evaluation. The method comprises the following steps: acquiring hospitalization information of a patient, microbiological inspection data and spatial layout information of an inpatient area to obtain initial data; judging whether a new case of drug-resistant bacteria is detected on the current day; if not, gradually reducing the historical aggregation degree by using an exponential decay formula until the historical aggregation degree returns to zero; if yes, calculating a newly added detection rate, a space aggregation degree and a time aggregation degree, and calculating a total aggregation degree of the day; dividing an inpatient area; dynamically generating a threshold value for the high-frequency inpatient area by adopting a quartile method to carry out abnormal value judgment, and identifying an abnormal aggregation degree for the low-frequency inpatient area by using a fixed absolute value threshold mechanism to obtain an early warning level; and early warning information of different levels is pushed according to the early warning level, and a prevention and control suggestion plan is attached. By implementing the method provided by the invention, the accuracy and efficiency of early warning can be remarkably improved, so that patients and medical personnel are better protected from the threat of drug-resistant bacterium infection.

The invention discloses a preparation method and antibacterial application of a naphthothiadiazolyl photosensitizer, and belongs to the technical field of biomedical antibacterial materials. The naphthothiadiazole-based photosensitizer provided by the invention overcomes the problem that the existing commercial photosensitizer gathers and quenches the active oxygen efficiency, and meanwhile, the antibacterial photosensitive polymer prepared based on the novel naphthothiadiazole-based photosensitizer has the unique advantages that the structure is stable, photosensitizer micromolecules are not easy to leak and the antibacterial effect is long-acting; the construction of the antibacterial polymer coating on the surface of the medical instrument in the future has important clinical application potential. The naphthothiadiazolyl photosensitizer provided by the invention has good photodynamic killing performance on drug-resistant bacteria MRSA (Methicillin Resistant Staphylococcus Aureus).

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

The invention provides a method for synchronously and rapidly detecting Escherichia coli and multiple drug-resistant genes thereof, which comprises the following steps: culturing a sample at night to obtain a bacterial solution to be detected, adding a buffer solution and a metal bath, centrifuging, taking a supernatant, detecting by micro-fluidic, optimizing the extraction process of nucleic acid in the sample, designing an optimal RPA primer probe group, and detecting the multiple drug-resistant genes of the Escherichia coli. A reasonable RPA coupled microfluidic detection system is established, synchronous and rapid detection of the escherichia coli uidA and I-type integrase gene intI1 thereof and drug-resistant genes sul1 and aadA5 is realized, the specificity is high, the sensitivity is high, the reaction time is short, the operation is convenient, and a method support is provided for monitoring and prevention and control of food-borne drug-resistant bacteria.

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

To provide a detection method capable of rapidly detecting drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas; a method for providing an index for selecting an antimicrobial agent for bacteria; and a primer set usable in these methods.SOLUTION: The detection method for drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas according to the present disclosure comprises a step of performing nucleic acid amplification of target genes (1) to (3) and (4) below for a target sample, and detecting drug-resistant bacteria, bacteria of the genus Staphylococcus, and bacteria of the genus Pseudomonas in the sample: (1) the mecA gene; (2) the spa gene of Staphylococcus aureus; (3) the tuf gene and / or the rpoB gene of bacteria of the genus Staphylococcus; and (4) the 16S rRNA gene of bacteria of the genus Pseudomonas.SELECTED DRAWING: Figure 1

The application provides a preparation method of a high-efficiency piezoelectric coating on a titanium implant surface. The preparation method of the application uses a hydrothermal treatment and an in-situ piezoelectric deposition technology to in-situ synthesize a nano strontium titanate-noble metal piezoelectric coating on the titanium implant surface. The coating can generate a piezoelectric potential and active oxygen through ultrasonic driving to degrade extracellular polymers and kill bacteria. In addition, the piezoelectric coating can also promote the osteogenic differentiation of bone marrow mesenchymal stem cells under piezoelectric stimulation, and finally realize the effects of bioactivity, long-acting drug-resistant bacteria and high-efficiency bone integration in the body. The application can provide a new surface treatment technology and research idea for controlling the drug-resistant bacteria infection on the implant surface, help to break through the limitations of the existing theory and technology in removing bacterial infection on the titanium implant surface, and provide beneficial guidance for the control of bacterial biofilm on other parts and the prevention and treatment of related infectious diseases.

The application belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide Mp-GC21, a precursor thereof and application. The amino acid sequence of the antibacterial peptide Mp-GC21 is shown as SEQ ID NO:1, wherein the C terminal is subjected to amidation modification, and two cysteines are connected through a disulfide bond; and the amino acid sequence of the precursor is shown as SEQ ID NO:3. The antibacterial peptide Mp-GC21 is separated from the flower frog, has broad-spectrum antibacterial activity, and has good bacteriostatic and bactericidal effects on standard strains and clinically derived drug-resistant strains of Acinetobacter baumannii, Escherichia coli and Staphylococcus aureus, and can target to destroy the cell membrane of bacteria, remove the biofilm and inhibit the formation of the biofilm. Moreover, the antibacterial peptide Mp-GC21 has good stability, does not have hemolytic activity, cytotoxicity and in-vivo toxicity, and is not easy to induce drug resistance of strains.

The application discloses antibacterial carbon dots and a low-temperature and normal-pressure preparation method and application thereof. The method is characterized in that ascorbic acid and cetylpyridinium chloride are used as raw materials, and the antibacterial carbon dots are synthesized through a low-temperature and normal-pressure method. The preparation method has the advantages of simple process, low reaction temperature, short reaction time, no need for any functional modification and low cost. The prepared carbon dots have good water solubility and excellent antibacterial activity. In particular, the carbon dots exhibit significant antibacterial activity on drug-resistant bacteria, can inactivate the drug-resistant bacteria through multiple ways such as destroying cell membranes, inducing active oxygen and reducing the surface charge of bacteria, and have a good application prospect in antibacterial aspects.

The application discloses a psoralen derivative or a pharmaceutical salt thereof, and a structure general formula of the psoralen derivative is shown in the following formula: The psoralen derivative is obtained by optimizing the structure of psoralen, and the antibacterial activity test is carried out on common gram-positive bacteria such as drug-resistant staphylococcus aureus and gram-negative bacteria such as escherichia coli and klebsiella pneumoniae, and it is found that the compound or the pharmaceutical salt thereof has excellent anti-drug-resistant bacteria, anti-inflammatory and anti-tumor activities, and has good development value in preparation of anti-infection treatment drugs, anti-inflammatory drugs and anti-tumor drugs.

The present invention relates to an antibacterial or antifungal composition and a pharmaceutical composition for preventing or treating bacterial or fungal infections, both comprising VLX600. The antibacterial composition comprising VLX600 according to one aspect of the present invention exhibits antibacterial or antifungal activity against a wide range of strains, including Mycobacterium spp., Escherichia spp., Pseudomonas spp., Staphylococcus spp., Acinetobacter spp., Candida spp., and the like. The pharmaceutical composition comprising VLX600 demonstrates excellent antibacterial, antifungal, and therapeutic efficacy against pathogens and can be effectively utilized for the prevention or treatment of bacterial or fungal infections. Furthermore, VLX600 exhibits a synergistic effect with conventional antibiotics and thus is effective in treating infections caused by antibiotic-resistant bacterial strains.

The invention relates to the field of biomedicine, and discloses a preparation method and application of an I-type composite photosensitizer with hydrogen sulfide detection performance. According to the invention, TPA-CHO and MN are adopted as monomers, a Schiff base reaction is adopted to synthesize a triphenylamine derivative TPAB with an A-pi-D-pi-A conjugated structure, Cu < 2 + > is further introduced into TPAB molecules, and a stable metal complex composite photosensitizer is formed through a coordinate bond. The functional composite photosensitizer TPAB-Cu < 2 + > has the characteristic of mainly generating I-type ROS and has efficient photodynamic bactericidal activity in an anoxic drug-resistant bacterium infection environment, and in addition, the functional molecule can be applied to drug-resistant bacterium infection microenvironment hydrogen sulfide level detection so as to realize early warning of drug-resistant bacterium infection and real-time detection of a treatment process; the technical problems that in an existing photodynamic therapy, the oxygen dependence of a photosensitizer is high, and the response sensitivity and specificity of a drug-resistant bacterium infection microenvironment are insufficient are solved.

The invention relates to a bimetallic alloy nano-enzyme for treating multi-drug-resistant bacterial infection as well as a preparation method and application thereof, and belongs to the field of biomedical nano-materials. The problems that in the prior art, the catalytic activity of metal and metal-based nano enzyme is limited, the bactericidal effect is poor due to poor targeting performance, the bactericidal effect in vivo (especially deep drug-resistant bacteria) is poor, and biocompatibility is poor are solved. The invention relates to a bimetallic alloy nano-enzyme for treating multidrug-resistant bacterial infection, which is mainly composed of two metal elements of Pt and Ru, and the atomic ratio of Pt / Ru is 90 / 10-70 / 30. The bimetallic alloy nano-enzyme disclosed by the invention has efficient biological catalytic activity, has a very good treatment effect on deep drug-resistant bacterial infection under ultrasonic activation, shows remarkable antibacterial, anti-biofilm and anti-inflammatory multiple effects, and is good in biocompatibility.

The present application belongs to the technical field of biomedical materials, and particularly relates to a composite extracellular trap antibacterial dressing and a preparation method thereof. The composite extracellular trap antibacterial dressing comprises a hydrogel and an extracellular trap loaded in the hydrogel. The antibacterial dressing can actively capture and efficiently kill bacteria including drug-resistant bacteria, is a novel dressing biological sterilization mechanism, has good biocompatibility, and can accelerate wound healing.

The invention discloses application of lactobacillus plantarum LP-Y01 and a fungicide thereof in preparation of a medicine for preventing and / or treating carbapenem-resistant drug-resistant bacterium infection. The invention verifies that the lactobacillus plantarum can generate a direct inhibition effect on carbapenem-resistant klebsiella pneumonia in vitro and has certain effective activity on colonization of the carbapenem-resistant klebsiella pneumonia in vivo through flora regulation and control. Probiotic pretreatment shows remarkable clinical potential by regulating and controlling a flora structure, provides a precise strategy for prevention and control of drug-resistant bacteria, and has a relatively good application prospect.

This invention relates to a method for preparing medical nanozymes, the medical nanozymes themselves, their applications, and pharmaceuticals, belonging to the field of biomedicine. It addresses at least one of the following problems in existing technologies for treating deep tissue infections caused by drug-resistant bacteria: poor antibacterial and anti-biofilm effects, insufficient deep tissue penetration, lack of inflammation regulation and tissue repair functions, biosafety risks, and high material preparation costs. The preparation method includes: mixing rhodium trichloride, urea, and polyvinylpyrrolidone to obtain a mixture; subjecting the mixture to staged pyrolysis under inert gas protection to obtain a nitrogen-doped carbon-supported single-atom rhodium catalyst; and modifying the nitrogen-doped carbon-supported single-atom rhodium catalyst with polyethylene glycol. The medical nanozymes prepared by this invention achieve excellent antibacterial and anti-biofilm effects both in vivo and in vitro, can regulate the inflammatory microenvironment, promote tissue repair, exhibit good biocompatibility, and have strong tissue penetration ability.

The application provides an application of a compound HEX and / or a compound POM-HEX in medicine for preventing and / or treating fungal infection, and belongs to the technical field of medicine. In vitro experiments show that POM-HEX alone has inhibiting effects on candida and cryptococcus, and when combined with fluconazole, the antifungal activity can be significantly improved, and the drug-resistant strains can restore the sensitivity to fluconazole. The organ bacterial load experiment in mice in vivo proves that POM-HEX can stably exert the drug efficacy in the organism. In addition, the IC 50 value of the metabolic product HEX of POM-HEX for inhibiting the Eno1 enzyme activity of Candida albicans is 1 / 30 of the IC 50 of HEX for inhibiting the Eno1 enzyme activity of human. The application discloses that the HEX and / or the compound have strong antifungal activity and high selectivity for the target point Eno1, provides a new idea for antifungal treatment, the drug combination can reduce the drug dosage, reduce the toxic and side effects, and solves the problem of fungal drug resistance.

Described herein is a synergistic combination comprising a quorum-sensing inhibitor and / or postbiotic metabolite and an antibiotic. Typically, the postbiotic metabolite comprises at least one peptide. Related compositions, uses, and methods are also described, including methods for resensitizing resistant bacteria to an antibiotic, and methods of treating antibiotic-resistant infections, such as methicillin-resistant Staphylococcus aureus (MRSA).

The invention relates to the technical field of biology, in particular to a protective monoclonal antibody targeting BCG (bacillus calmette guerin) BCG3965 as well as a preparation method and application of the protective monoclonal antibody. The antibody or an antigen binding fragment comprises a CDR sequence selected from at least one of the following sequences or a sequence with one amino acid substituted, deleted or increased: a heavy chain variable region CDR sequence: SEQ ID NO: 3-5; and the light chain variable region CDR sequences are as shown in SEQ ID NO: 7-9. The monoclonal antibody 5F10 shows efficient antituberculous activity in vivo and in vitro through specific targeting of BCG3965 protein on the surface of mycobacterium tuberculosis, mainly including the aspects of remarkably enhancing the phagocytosis of macrophages on tubercle bacillus, inhibiting tubercle bacillus growth and the like, and in addition, the monoclonal antibody 5F10 is clear in sequence and structure, easy to develop and modify, and capable of being used for preparing antituberculous drugs for treating mycobacterium tuberculosis. The monoclonal antibody 5F10 disclosed by the invention has the advantages that the monoclonal antibody 5F10 is not easy to induce pathogens to generate drug resistance by an immune-mediated treatment mechanism, and the monoclonal antibody 5F10 is applied to prevention and treatment of tuberculosis, not only provides a new choice for treatment of tuberculosis, but also provides an important technical basis for response of drug-resistant strains, development of diagnostic reagents, vaccine development and the like, and is wide in application prospect.

This invention belongs to the field of pharmaceutical technology, specifically relating to biomimetic nanomedicines for treating subcutaneous drug-resistant bacterial infections, their preparation methods, and applications. In this invention, dopamine hydrochloride is added during the synthesis of a metal-organic framework to prepare a dandelion-shaped carbon nanozyme precursor. This precursor is then carbonized to obtain a carbon nanozyme with targeting, photoresponsiveness, and peroxidase activity. Finally, berberine hydrochloride is loaded onto the carbon nanozyme to obtain the biomimetic nanomedicine. The biomimetic nanomedicine provided by this invention firstly possesses good biocompatibility; secondly, it has a unique dandelion-like morphology, which is beneficial for its targeting effect; and finally, it exhibits strong photoresponsiveness in the near-infrared region, enabling synergistic and efficient bactericidal action through the mechanisms of antibacterial drugs, photothermal therapy, and chemokinetics. It has significant application value in the preparation of drugs for treating subcutaneous drug-resistant bacterial infections.

The present application relates to the technical field of medical bandage, and discloses a biomass antibacterial hemostatic bandage and a functionalization method thereof.The bandage comprises a bandage base material and a composite antibacterial functional layer loaded thereon, the functional layer is composed of a composite antibacterial unit and lysozyme, and the composite antibacterial unit comprises a cationic antibacterial core, a polyphenol sustained-release shell and an enzymatic cellulose scaffold.The present application forms a biomass antibacterial hemostatic bandage with broad-spectrum, long-acting, low drug resistance and hemostatic function by constructing a cationic antibacterial core-polyphenol sustained-release shell-enzymatic cellulose scaffold composite antibacterial unit and synergistically loading lysozyme.The bandage shows significant technical advantages in dealing with complex wound infection, especially gram-negative bacterial infection and drug-resistant bacterial challenge, and provides an efficient and safe solution for clinical wound management, and has important clinical application value and broad market prospect.

The invention provides a compound for preparing an MBL and / or SBL enzyme inhibitor, application of the compound and a medicine of the compound, and belongs to the field of medicine. The structure of the compound is shown as a formula I. The compound provided by the invention has good and broad-spectrum inhibitory activity on clinically common metal beta lactamase (MBL) and serine beta lactamase (SBL), can be used as an MBL and / or SBL enzyme inhibitor, and is used for preparing antibacterial drugs, especially drugs for resisting drug-resistant bacteria. In addition, the compound disclosed by the invention is combined with beta-lactam antibiotic meropenem and the like for use, so that the compound has relatively good antibacterial activity on various beta-lactam antibiotic drug-resistant bacteria. The compound disclosed by the invention has great potential in preparation of MBL and SBL dual broad-spectrum inhibitors and medicines for resisting beta-lactam antibiotic-resistant bacteria. The invention provides a new choice for the use of antibacterial drugs, and has a good application prospect.

The invention discloses a microenvironment response type chessboard microneedle system and application thereof in treatment of drug-resistant bacteria infected wounds, and provides the microneedle system for solving the technical problems that in treatment of MRSA infected wounds, drugs are difficult to penetrate through wound surfaces and biological membrane barriers, the effective concentration of NO is difficult to maintain, and antibacterial-repair synergy is insufficient. The microneedle is formed by alternating hyaluronic acid and polyvinyl alcohol, ZCSO nano-enzyme and NO donor SNAP are loaded on the microneedle respectively, and the microneedle can penetrate through a physical barrier to accurately deliver functional components to a focus to achieve space targeting. The nidus microenvironment is triggered to release Cu < 2 + >, SNAP is catalyzed to continuously produce NO, time-space synchronization of NO and Cu < 2 + > is realized, and the NO gas therapy and copper-like death are used for synergistically resisting bacteria; se and Zn < 2 + > can relieve oxidative stress, regulate and control inflammation microenvironment and promote tissue regeneration. The system can efficiently remove MRSA and promote wound repair, provides a new strategy for treatment of drug-resistant bacteria infected wounds, and has a good clinical application prospect.

This application relates to the biomedical field and discloses a method for preparing a type I composite photosensitizer with both hydrogen sulfide detection capabilities and its uses. The invention synthesizes a triphenylamine derivative TPAB with an A-π-D-π-A conjugated structure using TPA-CHO and MN as monomers via a Schiff base reaction, and further incorporates Cu... 2+ By introducing TPAB molecules, a stable metal complex photosensitizer is formed through coordination bonds. This application presents the functional composite photosensitizer TPAB-Cu. 2+ Characterized primarily by the generation of type I ROS, it exhibits highly efficient photodynamic bactericidal activity in hypoxic environments infected with drug-resistant bacteria. Furthermore, this functional molecule can be used to detect hydrogen sulfide levels in the microenvironment of drug-resistant bacterial infections, enabling early warning and real-time monitoring of the treatment process. This solves the technical problems of strong oxygen dependence of photosensitizers and insufficient sensitivity and specificity in response to the microenvironment of drug-resistant bacterial infections in existing photodynamic therapies.